Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria
Study Identifier:
HEMRAV601IT
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Jun 2022 - Jun 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Ravulizumab
Date
Jun 2022 - Jun 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
This study will collect clinical response data on participants who were already treated with eculizumab for at least 26 weeks and who started ravulizumab treatment as a specific therapeutic strategy as per ordinary clinical practice.
Trial Locations
Location
Status
Location
Clinical Trial Site
Brescia, Italy
Status
N/A
Location
Clinical Trial Site
Catania, Italy
Status
N/A
Location
Clinical Trial Site
Lecce, Italy
Status
N/A
Location
Clinical Trial Site
Ragusa, Italy
Status
N/A
Location
Clinical Trial Site
Roma, Italy
Status
N/A
Location
Clinical Trial Site
Salerno, Italy
Status
N/A